Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab plus subcutaneous daratumumab versus DPd or DVd in relapsed or refractory multiple myeloma
CTR20221039Phase 3Active
- Sponsor
- Janssen Research & Development
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of teclistamab, daratumumab, pomalidomide, bortezomib, dexamethasone in multiple myeloma (MM), sponsored by Janssen Research & Development. Started Jul 2022; status: active.
02
Drugs
teclistamabdaratumumabpomalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20221039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221039.